ASCO: Everolimus Plus Herceptin Promising in Metastatic Breast Cancer

posted on Jun 06 by MedPage Today OB/Gyn in the Uncategorized category CHICAGO (MedPage Today) -- Adding the targeted agent everolimus (Afinitor) to therapy for women with metastatic breast cancer resistant to trastuzumab (Herceptin) results in clinical benefit for more than a third of patients, researchers said here.